These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


275 related items for PubMed ID: 9428731

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants.
    Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RM.
    J Biol Chem; 2001 Jul 20; 276(29):27207-13. PubMed ID: 11306576
    [Abstract] [Full Text] [Related]

  • 4. Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin.
    Shnyrov VL, Villar E, Zhadan GG, Sanchez-Ruiz JM, Quintas A, Saraiva MJ, Brito RM.
    Biophys Chem; 2000 Dec 15; 88(1-3):61-7. PubMed ID: 11152276
    [Abstract] [Full Text] [Related]

  • 5. Trapping the monomer of a non-amyloidogenic variant of transthyretin: exploring its possible use as a therapeutic strategy against transthyretin amyloidogenic diseases.
    Palhano FL, Leme LP, Busnardo RG, Foguel D.
    J Biol Chem; 2009 Jan 16; 284(3):1443-53. PubMed ID: 18984591
    [Abstract] [Full Text] [Related]

  • 6. The tetrameric protein transthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis.
    Quintas A, Saraiva MJ, Brito RM.
    J Biol Chem; 1999 Nov 12; 274(46):32943-9. PubMed ID: 10551861
    [Abstract] [Full Text] [Related]

  • 7. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions.
    Lashuel HA, Wurth C, Woo L, Kelly JW.
    Biochemistry; 1999 Oct 12; 38(41):13560-73. PubMed ID: 10521263
    [Abstract] [Full Text] [Related]

  • 8. Hydration and packing are crucial to amyloidogenesis as revealed by pressure studies on transthyretin variants that either protect or worsen amyloid disease.
    Ferrão-Gonzales AD, Palmieri L, Valory M, Silva JL, Lashuel H, Kelly JW, Foguel D.
    J Mol Biol; 2003 May 09; 328(4):963-74. PubMed ID: 12729768
    [Abstract] [Full Text] [Related]

  • 9. Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.
    Rodrigues JR, Simões CJ, Silva CG, Brito RM.
    Protein Sci; 2010 Feb 09; 19(2):202-19. PubMed ID: 19937650
    [Abstract] [Full Text] [Related]

  • 10. A New Folding Kinetic Mechanism for Human Transthyretin and the Influence of the Amyloidogenic V30M Mutation.
    Jesus CS, Almeida ZL, Vaz DC, Faria TQ, Brito RM.
    Int J Mol Sci; 2016 Aug 31; 17(9):. PubMed ID: 27589730
    [Abstract] [Full Text] [Related]

  • 11. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
    McCutchen SL, Lai Z, Miroy GJ, Kelly JW, Colón W.
    Biochemistry; 1995 Oct 17; 34(41):13527-36. PubMed ID: 7577941
    [Abstract] [Full Text] [Related]

  • 12. Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy.
    Taguchi K, Jono H, Kugimiya-Taguchi T, Nagao S, Su Y, Yamasaki K, Mizuguchi M, Maruyama T, Ando Y, Otagiri M.
    Life Sci; 2013 Dec 18; 93(25-26):1017-22. PubMed ID: 24211615
    [Abstract] [Full Text] [Related]

  • 13. Clusterin regulates transthyretin amyloidosis.
    Lee KW, Lee DH, Son H, Kim YS, Park JY, Roh GS, Kim HJ, Kang SS, Cho GJ, Choi WS.
    Biochem Biophys Res Commun; 2009 Oct 16; 388(2):256-60. PubMed ID: 19664600
    [Abstract] [Full Text] [Related]

  • 14. Why is Leu55-->Pro55 transthyretin variant the most amyloidogenic: insights from molecular dynamics simulations of transthyretin monomers.
    Yang M, Lei M, Huo S.
    Protein Sci; 2003 Jun 16; 12(6):1222-31. PubMed ID: 12761393
    [Abstract] [Full Text] [Related]

  • 15. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
    Lai Z, Colón W, Kelly JW.
    Biochemistry; 1996 May 21; 35(20):6470-82. PubMed ID: 8639594
    [Abstract] [Full Text] [Related]

  • 16. Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants.
    Schwarzman AL, Tsiper M, Wente H, Wang A, Vitek MP, Vasiliev V, Goldgaber D.
    Amyloid; 2004 Mar 21; 11(1):1-9. PubMed ID: 15185492
    [Abstract] [Full Text] [Related]

  • 17. Dissecting the structure, thermodynamic stability, and aggregation properties of the A25T transthyretin (A25T-TTR) variant involved in leptomeningeal amyloidosis: identifying protein partners that co-aggregate during A25T-TTR fibrillogenesis in cerebrospinal fluid.
    Azevedo EP, Pereira HM, Garratt RC, Kelly JW, Foguel D, Palhano FL.
    Biochemistry; 2011 Dec 27; 50(51):11070-83. PubMed ID: 22091638
    [Abstract] [Full Text] [Related]

  • 18. Binding of amyloidogenic transthyretin to the plasma membrane alters membrane fluidity and induces neurotoxicity.
    Hou X, Richardson SJ, Aguilar MI, Small DH.
    Biochemistry; 2005 Aug 30; 44(34):11618-27. PubMed ID: 16114899
    [Abstract] [Full Text] [Related]

  • 19. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.
    Hurshman Babbes AR, Powers ET, Kelly JW.
    Biochemistry; 2008 Jul 01; 47(26):6969-84. PubMed ID: 18537267
    [Abstract] [Full Text] [Related]

  • 20. Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities.
    Foguel D, Suarez MC, Ferrão-Gonzales AD, Porto TC, Palmieri L, Einsiedler CM, Andrade LR, Lashuel HA, Lansbury PT, Kelly JW, Silva JL.
    Proc Natl Acad Sci U S A; 2003 Aug 19; 100(17):9831-6. PubMed ID: 12900507
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 14.